[Complete response to durvalumab+tremelimumab as second-line therapy after atezolizumab+bevacizumab in peritoneal recurrence after liver resection: a case report].
Shu Inagaki, Yukiyasu Okamura, Hayato Abe, Osamu Aramaki
{"title":"[Complete response to durvalumab+tremelimumab as second-line therapy after atezolizumab+bevacizumab in peritoneal recurrence after liver resection: a case report].","authors":"Shu Inagaki, Yukiyasu Okamura, Hayato Abe, Osamu Aramaki","doi":"10.11405/nisshoshi.123.421","DOIUrl":null,"url":null,"abstract":"<p><p>A male patient in his 70s experienced peritoneal dissemination recurrence after resection for hepatocellular carcinoma. The disease progressed despite initial atezolizumab+bevacizumab combination therapy. Consequently, durvalumab+tremelimumab combination therapy was initiated. After one treatment course, the peritoneal disseminated lesions reduced in size, and the protein induced by vitamin K absence or antagonist-II (PIVKA-II) values remarkably decreased. After seven chemotherapy courses, the peritoneal disseminated lesions disappeared, and the PIVKA-II values decreased to normal levels. Peritoneal recurrence after liver resection is generally considered to have a poor prognosis. This case report describes the remarkable efficacy of a combination therapy with durvalumab+tremelimumab after atezolizumab+bevacizumab in advanced hepatocellular carcinoma.</p>","PeriodicalId":35808,"journal":{"name":"Japanese Journal of Gastroenterology","volume":"123 6","pages":"421-427"},"PeriodicalIF":0.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11405/nisshoshi.123.421","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
A male patient in his 70s experienced peritoneal dissemination recurrence after resection for hepatocellular carcinoma. The disease progressed despite initial atezolizumab+bevacizumab combination therapy. Consequently, durvalumab+tremelimumab combination therapy was initiated. After one treatment course, the peritoneal disseminated lesions reduced in size, and the protein induced by vitamin K absence or antagonist-II (PIVKA-II) values remarkably decreased. After seven chemotherapy courses, the peritoneal disseminated lesions disappeared, and the PIVKA-II values decreased to normal levels. Peritoneal recurrence after liver resection is generally considered to have a poor prognosis. This case report describes the remarkable efficacy of a combination therapy with durvalumab+tremelimumab after atezolizumab+bevacizumab in advanced hepatocellular carcinoma.
期刊介绍：
The Journal of Gastroenterology, which is the official publication of the Japanese Society of Gastroenterology, publishes Original Articles (Alimentary Tract/Liver, Pancreas, and Biliary Tract), Review Articles, Letters to the Editors and other articles on all aspects of the field of gastroenterology. Significant contributions relating to basic research, theory, and practice are welcomed. These publications are designed to disseminate knowledge in this field to a worldwide audience, and accordingly, its editorial board has an international membership.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
